Company

Bank

Analyst

Coverage

Opinion

Wk chg

1/3 cls

Coronado Biosciences Inc. (NASDAQ:CNDO)

Oppenheimer

Boris Peaker

Downgrade

Market perform (from outperform)

1%

$2.78

Peaker also removed his $2.50 target due to uncertainty about Coronado's Trichuris suis ova (TSO). TSO missed the primary endpoint in the Phase II TRUST-I trial in October, and partner Dr. Falk Pharma GmbH discontinued the Phase II TRUST-II trial for lack of efficacy in November (see BioCentury, Nov. 11, 2013). TSO comprises ova from T. suis, a porcine helminth. TSO is also in investigator-initiated Phase II trials to treat ulcerative colitis, multiple sclerosis (MS), autism and psoriasis.

Endo Health Solutions Inc. (NASDAQ:ENDP)

Cantor Fitzgerald

Irina Rivkind

Downgrade

Sell (from hold)

-2%

$65.17